
Opinion|Videos|February 18, 2025
The Future of Neurokinin-Targeted Therapies in Patients With VMS
Author(s)Alexa N. Fiffick, D.O., MBS, MSCP
A panelist discusses how neurokinin-targeted therapies can be strategically combined with existing treatments to address multiple vasomotor symptoms (VMS) while highlighting their positive impact on patient quality of life, noting ongoing needs for long-term safety data and improved accessibility.
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following:
- How might these therapies fit into combination treatment strategies, and what combinations seem most promising?
- How do you see the broader implications of neurokinin-targeted therapies on patient outcomes and quality of life? What are the unmet needs with these therapies?
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
7 things you need to know about the PBM reforms signed into law this week
2
PBM reform. It has finally happened
3
TrumpRx launches; some experts question its long-term value
4
FDA issues draft guidance on MRD and complete response as primary endpoints for accelerated multiple myeloma drug approvals
5























